Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients-Reference-Cited by-同舟云学术

Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients

Published:2021-06-29 Issue:16-2 Volume:16 Page:140-147
ISSN:2687-1955
Container-title:Yeni Üroloji Dergisi
language:
Short-container-title:New J Urol

Author:

Yılmaz Sercan¹^ORCID,Aybal Halil Cagri²^ORCID,Özdemir Hakan³^ORCID,Gazel Eymen⁴^ORCID,Kaya Engin¹^ORCID,Yalcin Serdar¹^ORCID,Yilmaz Mehmet⁵^ORCID,Oner Ali Yusuf⁶^ORCID,Yorubulut Mehmet⁷^ORCID,Tunc Lutfi⁸^ORCID

Affiliation:

1. University of Health Sciences, Gulhane Training and Research Hospital, Department of Urology, Ankara, Turkey

2. Kahramankazan Hamdi Eris State Hospital, Department of Urology, Ankara, Turkey

3. Diason Ultrasonography Center, Ankara, Turkey

4. Acıbadem University Ankara Hospital, Department of Urology, Ankara, Turkey

5. Zile State Hospital, Department of Urology, Tokat, Turkey

6. Gazi University School of Medicine, Department of Radiology, Ankara, Turkey

7. Acibadem University, Ankara Hospital, Department of Radiology, Ankara, Turkey

8. Gazi University School of Medicine, Department of Urology, Ankara, Turkey

Abstract

Objective: We aimed to evaluate magnetic resonance imaging-ultrasound guided fusion prostate biopsy (MRI- US FPBx) results from a single center and to compare with current literature. Material and Methods: Between January 2016 and July 2019, MRI-US FPBx pathological and imaging results of 358 men were retrospectively analyzed. PI-RADS scores were determined as 3, 4 and 5 in 222 (62%), 107 (29.8%) and 29 (8.1%) patients, respectively. Totally 454 lesions were underwent MRI-US FPBx. 303 (66.7%) lesions were scored as PI-RADS 3, 120 (26.4%) lesions were scored as PI-RADS 4 and 31 (6.8%) lesions were scored as PI-RADS 5. 315 (69.3%) of lesions were in peripheral zone, 26 (5.7%) were in central zone, 111 (24.4%) were in transitional zone and 2 of them were in anterior fibromuscular stroma. Results: Overall prostate cancer detection rate was 36.3%. Concerning detection rates, MRI-US FPBx alone and transrectal ultrasonography guided prostate biopsy (TRUS-Bx) alone were 27.6% and 26.5%, respectively. Cancer detection rate only through MRI-US FPBx PIRADS-3 and PI-RADS 4&5 were 6.9% and 20.6%, respectively. Clinically significant prostate cancer (csPCa) rates were evaluated and csPCa to overall prostate cancer (PCa) rates for TRUS-Bx, MRI-US FPBx and combined techniques were 16.8%, 35.4% and 39.2%, respectively. Results of 11 patients were evaluated as benign. Conclusion: MRI-US FPBx significantly increases success rate of prostate biopsy procedure. Regarding current MRI technology, it is not appropriate to consider MRI-US FPBx as a stand-alone biopsy option without concomitant with TRUS-Bx. Keywords: prostate cancer; biopsy; MRI; fusion

Publisher

Avrasya Uroonkoloji Dernegi

Reference30 articles.

1. 1. Hernandez-Aragues I, Baniandres-Rodriguez O. Basal cell carcinoma of the scrotum. Actas Urol Esp. 2016;40:592-3.10.1016/j.acuro.2016.04.013.

2. 2. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med. 2011;365:2013-9.10.1056/NEJMcp1103642.

3. 3. Quon JS, Moosavi B, Khanna M, et al. False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging. 2015;6:449-63.10.1007/s13244-015-0411-3.

4. 4. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics. 2011;31:677-703.10.1148/rg.313105139.

5. 5. Siddiqui MM, George AK, Rubin R, et al. Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. J Natl Cancer Inst. 2016;108.10.1093/jnci/djw039.